文献速递眼整形与眼眶角膜与眼表疾病

浸润性结膜鳞状细胞癌的辅助质子束放疗:全身、眼部及视力结局

Adjuvant proton beam irradiation for invasive conjunctival squamous cell carcinoma: systemic, ocular and visual outcomes.
PubMed 文献 · Br J Ophthalmol · 2026-09-25

该回顾性研究纳入66例浸润性结膜鳞状细胞癌患者,在手术切除后4个月内接受辅助质子束放疗(60 Gy分8次,基于术前照片/绘图、不使用钽夹)。平均随访3.7年,肿瘤控制率95.5%,局部复发率4.5%,无转移,64%患者末次随访视力优于20/30。

要点

  • 辅助质子束放疗对浸润性结膜鳞状细胞癌局部控制率95.5%,无转移发生。
  • 局部复发者诊断时病变较大且更常累及穹窿/睑结膜。
  • 64%患者末次随访视力优于20/30,1例因新生血管性青光眼行眼球摘除。

核心结论

  • 浸润性结膜鳞状细胞癌切除后辅助质子束放疗可获得极佳的局部控制,并带来良好的全身、眼部及视力结局。

研究设计与样本

  • 回顾性纳入2006至2019年间在切除后4个月内接受质子束放疗(60 Gy分8次,基于术前照片/绘图、不使用钽夹)的连续浸润性结膜鳞状细胞癌患者,排除着色性干皮病患者。

主要发现

  • 66例患者(男50例、女16例,平均年龄67.4±13.4岁),平均随访3.7年,肿瘤控制63例(95.5%)。
  • 3例(4.5%)出现局部复发(2例原位癌、1例异型增生),平均发生于质子束放疗后12.6个月。
  • 复发患者诊断时病变较大(p=0.041)且更常累及穹窿/睑结膜(p=0.010)。
  • 无患者发生结膜鳞状细胞癌转移;4例(6.0%)死亡(2例其他癌症、2例原因不明)。
  • 1例发生新生血管性青光眼需二次眼球摘除;42例(64%)末次随访视力优于20/30。

关键数值与推荐

  • 质子束放疗剂量为60 Gy分8次,基于术前照片/绘图定位、不使用钽夹。
  • 随访包括每6个月颈部超声或PET扫描至少2年。
  • 复发患者诊断时病变较大(p=0.041)且更常累及穹窿/睑结膜(p=0.010)。

临床怎么用

  • 对浸润性结膜鳞状细胞癌切除后应考虑辅助质子束放疗以降低局部复发。
  • 对于病变较大且累及睑结膜者,可考虑使用钽夹的质子束放疗或其他照射方式。

局限性

  • 回顾性研究设计。
  • 样本量66例,平均随访3.7年。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Invasive conjunctival squamous cell carcinoma (cSCC) carries a risk of local/distant recurrence after surgical excision. Adjuvant treatment is therefore required. We aimed to evaluate the outcome of adjuvant proton beam therapy (PBT) after excision of cSCC, in terms of overall survival, local/distant recurrence, eye conservation and vision. METHODS: Consecutive patients with invasive cSCC, who received PBT (60 Gy in 8 fractions based on preoperative photographs/drawings without tantalum clips) within 4 months of excision between 2006 and 2019, were retrospectively included. Cases with xeroderma pigmentosum were excluded. Follow-up included neck ultrasound or positron emission tomography-scan every 6 months for at least 2 years. RESULTS: 66 patients were included (50 men, 16 women, mean age 67.4±13.4 years). Two presented immunosuppression. Over a mean follow-up of 3.7 years, tumour control was achieved in 63 patients (95.5%). Three patients presented local recurrence (4.5%), including two in situ cSCC and one dysplasia with a mean delay of 12.6-month after PBT. Relapsing patients had larger lesions (p=0.041) and more frequent fornix/tarsal conjunctiva involvement (p=0.010) at diagnosis. No patient developed metastases from cSCC. Four patients died during follow-up (6.0%): two from other cancers and two from unknown causes. One patient developed neovascular glaucoma requiring secondary enucleation. 42 patients (64%) retained visual acuity better than 20/30 at the last visit. CONCLUSION: Adjuvant PBT for invasive cSCC provides excellent local control and is associated with favourable systemic, ocular and visual outcomes. PBT with tantalum clips, or alternative irradiation modalities, should be considered for large tumours extending to the tarsal conjunctiva.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Le Boité H, Dendale R, Dureau S, et al. Adjuvant proton beam irradiation for invasive conjunctival squamous cell carcinoma: systemic, ocular and visual outcomes. Br J Ophthalmol. 2026. PMID: 42791050. doi:10.1136/bjo-2025-328127

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。